Achillion Pharmaceuticals has entered into an agreement with Imperial College London to conduct a natural history study of C3 glomerulopathy (C3G).

This is a rare renal disorder which includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). C3G affects an estimated 8,000 people across Europe and the United States.​

more